HK Stock Market Move | Brainaurora-B (06681) and Nanjing Panda (00553) saw their stock prices rise by over 4%, as the concept of brain-machine interfaces becomes popular again.
Brain-computer interface concept stocks are active again. As of the time of publication, BrainCo-A (06681) rose by 4.81% to 4.58 Hong Kong dollars; Nanjing Panda Electronics Co., Ltd. (00553) rose by 4.45% to 5.63 Hong Kong dollars.
The concept of brain-computer interfaces (BCI) stocks has once again become active. As of the time of writing, BRAINAURORA-B (06681) rose by 4.81% to HK$4.58; NANJING PANDA (00553) rose by 4.45% to HK$5.63; MICROPORT NEURO (02172) rose by 2.87% to HK$11.13.
In terms of news, it was proposed in the government work report to establish a future industry investment risk-sharing mechanism, to foster the development of brain-computer interfaces and other future industries. EB SECURITIES believes that in the context of deepening the "artificial intelligence+" initiative, the medical field has the potential to reshape the underlying logic of medical service efficiency through large model-driven assisted diagnosis and treatment, precision drug development, and personalized health management. BCI, as the ultimate fusion of life sciences and information technology, is included in the government's future industry planning, signaling the acceleration of the establishment of related ethical, regulatory, and commercialization pathways.
Related Articles

HK Stock Market Move | ASCENTAGE-B(06855) up over 5% again, the company will welcome multiple milestones and catalyst events this year.

HK Stock Market Move | CSTONE PHARMA-B (02616) rises by more than 9%, included in the FTSE China Small Cap Stock Index, rapid progress in the clinical research of three anti-tumor drug candidates.

HK Stock Market Move | IMMUNEONCO-B(01541) surged over 16%, Amonirufu subcutaneous formulation IMM0306S for the treatment of systemic lupus erythematosus was approved for IND.
HK Stock Market Move | ASCENTAGE-B(06855) up over 5% again, the company will welcome multiple milestones and catalyst events this year.

HK Stock Market Move | CSTONE PHARMA-B (02616) rises by more than 9%, included in the FTSE China Small Cap Stock Index, rapid progress in the clinical research of three anti-tumor drug candidates.

HK Stock Market Move | IMMUNEONCO-B(01541) surged over 16%, Amonirufu subcutaneous formulation IMM0306S for the treatment of systemic lupus erythematosus was approved for IND.

RECOMMEND





